Normalization of complement activation and consumption in diabetic children and adolescents after switch-over from porcine to semisynthetic human insulin.
As the use of human insulin could possibly modify the immunogenicity of insulin, the present prospective study compares complement evaluation (CH50, C3, C3d/C3, C4) as well as other immunological factors (insulin antibodies, autoantibodies, ...), metabolic control (HbA1, lipids, ...) and clinical data (insulin dose/kg, number of hypoglycaemic episodes, ...), before and after a switch-over from monocomponent porcine insulins (Actrapid MC, Monotard MC) to human semisynthetic insulins (Actrapid HM, Protaphane HM). Forty-six type I diabetic children and adolescents (mean age +/- SD: 14.3 +/- 3.8 years) participated in the trial. The duration of diabetes ranged from 1.0 to 16.9 years (mean +/- SD: 7.3 +/- 3.7). The study protocol consisted of a 9 month period during which, at monthly intervals, the subjects were assessed clinically and blood samples taken for measurement of biological data. After 3 months, porcine insulins were switched to human insulins. The main results were as follows: 1) The insulin dose/kg was increased after the switch-over (porcine insulin: 0.90 +/- 0.03 U/kg; human insulin: 0.98 +/- 0.03 U/kg; p less than 0.001). This can perhaps be explained by the different bioavailabilities of Monotard MC and Protaphane HM. 2) The objective degree of metabolic control (HbA1), as well as the HDL-cholesterol level and the apo A1/B ratio, were not statistically different before and after the switch-over. 3) IgG insulin antibody binding was not statistically different on transfer from porcine insulin to semisynthetic insulin. 4) Mean level of total IgE and IgE specific insulin antibodies, determined before and after the switch-over, were not different. 5) Autoantibodies and antinuclear factor were unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)
Dorchy
H
H
Diabetes Unit, Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.
Duchateau
J
J
D'Hooge
D
D
D000293:Adolescent; D000328:Adult; D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D002648:Child; D008076:Cholesterol, HDL / Q000097:blood; D003167:Complement Activation; D003165:Complement System Proteins / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007328:Insulin / Q000627:therapeutic use*; D007330:Insulin Antibodies / Q000032:analysis; D007336:Insulin, Isophane / Q000627:therapeutic use*; D061389:Insulin, Regular, Pork; D008297:Male; D013552:Swine
D001786:Blood Glucose; D008076:Cholesterol, HDL; D003165:Complement System Proteins; D006442:Glycated Hemoglobin; D007136:Immunoglobulins; D007328:Insulin; D007330:Insulin Antibodies; D007336:Insulin, Isophane; D061389:Insulin, Regular, Pork; C000006:insulin, neutral